首页> 外文OA文献 >Prospective Study Evaluating IncobotulinumtoxinA for Cervical Dystonia or Blepharospasm: Interim Results from the First 145 Subjects with Cervical Dystonia
【2h】

Prospective Study Evaluating IncobotulinumtoxinA for Cervical Dystonia or Blepharospasm: Interim Results from the First 145 Subjects with Cervical Dystonia

机译:评价IncobotulinumtoxinA的宫颈肌张力障碍或眼睑痉挛的前瞻性研究:145例宫颈肌张力障碍患者的中期结果

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background: We report the interim results from XCiDaBLE: A large prospective, observational "naturalistic" study evaluating Xeomin® (incobotulinumtoxinA) for cervical dystonia or blepharospasm in the United States. Methods: Subjects with CD are followed for 2 treatment cycles and monitored via Interactive Voice/Web Response. Subject-reported scales include the Subject Global Impression-Severity and Improvement; Cervical Dystonia Impact Profile (CDIP-58); and Work Productivity and Quality of Life (QoL) are assessed by means of an employment questionnaire and work history and the SF-12v2. Results: This ongoing study includes 145 subjects with a diagnosis of CD. The majority were female (82.3%) and White (91.0%) and had previously been treated with botulinum toxins (77.2%). There were 106 employed at the time of onset of the disease, but 12.6 years later only 44% were still employed at the time of enrolment into the study and 20% were either receiving or seeking disability benefits. However, only 44% were still employed at the time of recruitment for study participation. The mean total dose/treatment of CD was 225.2 units for the 1st injection. The CDIP-58 total score was significantly improved at four weeks post the first injection compared to baseline (p less than or equal to 0.0001). Most subjects noted improvement in their global impression assessment. No new or unexpected adverse events occurred. Discussion: The results from these interim analyses confirm previous controlled single-dose studies of incobotulinumtoxinA in terms of efficacy and safety.
机译:背景:我们报道了XCiDaBLE的中期结果:一项大型前瞻性,观察性“自然”研究,评估Xeomin®(incobotulinumtoxinA)在美国的宫颈肌张力障碍或眼睑痉挛。方法:对患有CD的受试者进行2个治疗周期的随访,并通过Interactive Voice / Web Response进行监测。主题报告的量表包括主题全球印象-严重性和改进;宫颈肌张力障碍影响概况(CDIP-58);通过工作问卷,工作经历和SF-12v2评估工作效率和生活质量(QoL)。结果:这项正在进行的研究包括145名诊断为CD的受试者。多数是女性(82.3%)和白人(91.0%),之前曾接受肉毒杆菌毒素治疗(77.2%)。疾病发作时有106名雇员,但是12.6年后,在纳入研究时仍只有44%的雇员被雇用,而20%的人正在接受或寻求残疾津贴。但是,在招募参加研究的人员时,仍然只有44%被雇用。第一次注射CD的平均总剂量/治疗为225.2单位。与基线相比,首次注射后第4周CDIP-58总分明显提高(p小于或等于0.0001)。大多数受试者注意到他们的总体印象评估有所改善。没有新的或意外的不良事件发生。讨论:这些中期分析的结果证实了以往关于incobotulinumtoxinA的受控单剂量研究的有效性和安全性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号